Well-Controlled Comparative Study and Open Clinical Study of 0.05% Hydrocortisone-17-Butyrate Ointment (TS-1020)/TS-1020 Clinical Study Group

Hiroshi Ueda, Ritsuko Hayakawa, Kayoko Matsunaga

Research output: Contribution to journalArticlepeer-review

Abstract

TS-1020 (TS) is a proprietary steroidal ointment which contains 0.05% hydrocortisone-17-butyrate. Locoid® Ointment (LO), which contains 0.1% of the topical steroid, has been generally used since 1975 as an ethical steroidal ointment. The vehicles of the two ointments are the same. In order to elucidate the clinical efficacy and safety of TS, well-controlled comparative study was perfromed in comparison with LO in 85 patients with moist type of eczema for 1 week application. The results showed that the efficacy rate of TS was 78.1%, whereas that of LO was 79.5%. The difference between TS and LO was not statistically significant. Then open clinical study of TS was done in 218 cases with moist type of eczema, lichenificated type of eczema, prurigo and hand eczema. The efficacy rates were 83. 3% (67/126 cases) in moist type of eczema, 79.6% (31/54 cases) in lichenificated type of eczema and 69.0% (16/29 cases) in chronic prurigo and hand eczema. Any side effect was noticed in the open clinical study. Therefore we concluded that TS is an excellent proprietary steroidal ointment with efficacy and safety.

Original languageEnglish
Pages (from-to)248-267
Number of pages20
Journalskin research
Volume31
Issue number2
DOIs
Publication statusPublished - 17-10-1989
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Well-Controlled Comparative Study and Open Clinical Study of 0.05% Hydrocortisone-17-Butyrate Ointment (TS-1020)/TS-1020 Clinical Study Group'. Together they form a unique fingerprint.

Cite this